Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Cyclacel Pharma (CYCC) Tops Q3 EPS by 8c
November 11, 2020 4:36 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.47), $0.08 better than the analyst estimate of ($0.55).
We continue to execute on our clinical development plan for fadraciclib and CYC140 in both liquid and solid cancers, said Spiro Rombotis, President and Chief Executive Officer. The recent ENA presentation... More
